| C |
|
C2 DOMAIN T-CELL EPITOPES IN HEMOPHILIA A SUBJECTS WITH THE MUTATION A2201P
|
| Ettinger R.A., James E.A., Thompson A.R., Kwok W.W., Pratt K.P. |
| |
|
C936T MUTATION IN THE VEGF GENE AS AN INDEPENDENT RISK FACTOR FOR PATIENTS WITH SILENT BRAIN INFARCTION
|
| Kim N., Hong S., Kim O., Kim H., Park H., Bae S., Oh D. |
| |
|
CALCIUM PUMPS AND ER STRESS MODULATIONS DURING THROMBOPOIESIS
|
| Bobe R., Châabane C., Polidano E., Bredoux R., Corvazier E., Dally S., Debili N., Nurden P., Enouf J. |
| |
|
CALDAG-GEFI-DEFICIENCY CAUSES IMPAIRED BETA1, BETA2, AND BETA3 INTEGRIN ACTIVATION IN NEUTROPHILS AND PLATELETS: A MODEL FOR LEUKOCYTE ADHESION DEFICIENCY-III (LAD-III)
|
| Goerge T., Bergmeier W., Wang H., Crittenden J.R., Baldwin A.C.W., Cifuni S.M., Housman D.E., Graybiel A.M., Wagner D.D. |
| |
|
CAMP-INDUCED INHIBITION OF CA2+ MOBILIZATION IS REVERSED BY TYROSINE PHOSPHORYLATION OF IP3R IN PLATELETS
|
| Riondino S., Borgognone A., Marotta S., Pulcinelli F.M. |
| |
|
CAN BLOOD HIPERVISCOSITY BE A PREDICTOR OF ACUTE CORONARY SYNDROME?
|
| Quintana M., Sevilla J., Sanchez M., Taberna M. |
| |
|
CAN THROMBIN GENERATION (TG) BE USED TO MONITOR RFVIIA TREATMENT: IN VIVO "MINI-PK" STUDY IN HEMOPHILIA A PATIENTS
|
| Livnat T., Martinowitz U., Tamarin I., Ravid B., Zivelin A., Kenet G. |
| |
|
CAN THROMBIN GENERATION BE HELPFUL TO EVALUATE THE BLEEDING PHENOTYPE IN MILD HEMOPHILIA A WITH FACTOR VIII ASSAY DISCREPANCY?
|
| Trossaert M., Regnault V., Sigaud M., Boisseau P., Fressinaud E., Lecompte T. |
| |
|
CANCER AND THROMBOSIS: FROM MOLECULAR MECHANISMS TO CLINICAL PRESENTATIONS
|
| Buller H.R., van Doormaal F., van Sluis G.L., Kamphuisen P.W. |
| |
|
CANCER AND VENOUS THROMBOEMBOLISM: ROLE OF GENETIC POLYMORPHISMS IN SELECTINS AND TISSUE FACTOR
|
| Reverter J.C., Font C., Monteagudo J., Corbella M., Freire C., Pijoan J., Gascon P., Tassies D. |
| |
|
CANCER-ASSOCIATED THROMBOSIS: TISSUE FACTOR-BEARING MICROPARTICLES ARE ASSOCIATED WITH AN INCREASED RISK OF VENOUS THROMBOEMBOLIC EVENTS IN CANCER PATIENTS
|
| Zwicker J.I., Kos C.A., Johnston K.A., Liebman H.A., Furie B.C., Furie B. |
| |
|
CANOLA OIL, BUT NOT SUNFLOWER OIL, DECREASES CHOLESTEROL AND IMPROVES ENDOTHELIAL FUNCTION IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE: A DOUBLE-BLIND, RANDOMIZED INTERVENTIONAL STUDY
|
| Stricker H., Duchini F., Facchini M., Mombelli G. |
| |
|
CAPACITY OF SOLVENT-DETERGENT TREATMENT AND NANOFILTRATION APPLIED TO FVIII/VWF AND FIX PURIFICATION PROCESSES TO ELIMINATE EMERGING VIRAL PATHOGENS
|
| Caballero S., Otegui M., Domingo N., Garaigorta U., Ortín J., Gajardo R., Jorquera J.I. |
| |
|
CARDIAC tPA RELEASE DURING SYMPATHETIC NERVE STIMULATION IN PIGS DECREASES BY REPEATED STIMULATIONS
|
| Aspelin T., Eriksen M., Björkman J.A., Lyberg T., Ilebekk A. |
| |
|
CARDIOVASCULAR DISEASE, HYPERHOMOCYSTEINEMIA AND ATHEROTHROMBOTIC RISK FACTORS IN PSORIATIC PATIENTS
|
| Longoni R., Fornara L., Bocchi L., Montani N., Brazzelli V., Gamba G. |
| |
|
CARDIOVASCULAR RISK FACTORS AND VENOUS THROMBOEMBOLISM: A META-ANALYSIS
|
| Ageno W., Becattini C., Brighton T., Selby R., Kamphuisen P.W. |
| |
|
CARDIOVASCULAR RISK FACTORS ARE ASSOCIATED WITH PLASMA MARKERS OF PRO-ATHEROGENIC PROCESSES IN RHEUMATOID ARTHRITIS
|
| Blann A.D., Bhatia G., Sosin M., Grindulis K., Khattak H., Lip G. |
| |
|
CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME PRESENTING WITH ISOLATED ANTI-BETA2 GLYCOPROTEIN I ANTIBODY POSITIVITY
|
| Millar C.M., Chowdary P., Vinayagam S., Beynon H., Tuddenham E.G. |
| |
|
CATECHOL-O-METHYLTRANSFERASE GENOTYPE IS ASSOCIATED WITH PLASMA TOTAL HOMOCYSTEINE LEVELS AND MAY INCREASE RECURRENT VENOUS THROMBOSIS RISK
|
| Gellekink H., Muntjewerff J., Vermeulen S., Hermus A.R., Blom H.J., den Heijer M. |
| |
|
CATHEPSIN G IS NOT A SPECIFIC AGONIST FOR PROTEASE ACTIVATED RECEPTORS IN PLATELETS
|
| Brugge J.M., Van kerckhoven S., Nemmar A., Hoylaerts M.F. |
| |
|
CATHETER RELATED THROMBOSES IN INFANTS AND CHILDREN
|
| Manco-Johnson M.J. |
| |
|
CATHETER-RELATED THROMBOSES IN NEWBORNS
|
| Ehlen M., Wiebe B., Pohlmann U., Wiebe W., Hertfelder H. |
| |
|
CAUSE OF DEATH AMONG PATIENTS WITH LOCAL OR REGIONAL STAGE CANCER OF THE BREAST AND LUNG WHO DEVELOP VENOUS THROMBOEMBOLISM (VTE)
|
| Wun T., Chew H., Zhou H., Harvey D., White R. |
| |
|
CBL-B: A PHYSIOLOGICALLY IMPORTANT SIGNALING MOLECULE FOR COLLAGEN-DEPENDENT ACTIVATION
|
| Dangelmaier C.A., Mada S., Jianguoi J., Kunapuli S.P., Daniel J.L. |
| |
|
CD148 IS A POSITIVE REGULATOR OF PLCGAMMA2 ACTIVATION BY GPVI
|
| Ellison S.M., Tomlinson M.G., Zhu J., Weiss A., Watson S.P., Senis Y.A. |
| |
|
CD148 IS AN ESSENTIAL POSITIVE REGULATOR OF ITAM AND INTEGRIN RECEPTOR SIGNALLING IN PLATELETS
|
| Senis Y.A., Tomlinson M.G., Zhu J., Ellison S.M., Protty M.B., Weiss A., Watson S.P. |
| |
|
CD36 AND SRA GENE EXPRESSION IN HUMAN CAROTID ENDARTERECTOMY LESIONS
|
| Collot-Teixeira S., Bultelle F., Pasterkamp G., Barbatis C., Tedgui A., McGregor J.L. |
| |
|
CD72 POLYMORPHISM ASSOCIATED WITH SUSCEPTIBILITY TO IDIOPATHIC THROMBOCYTOPENIA PURPURA IN CHINESE PATIENTS
|
| Xu J., Lu S., Tao J., Zhou Z., Chen Z., Huang Y., Yang R. |
| |
|
CELL-DERIVED MICROPARTICLES AND COMPLEMENT ACTIVATION IN PREECLAMPSIA VERSUS NORMAL PREGNANCY
|
| Biro E., Lok C.A.R., Hack C.E., van der Post J.A.M., Schaap M.C.L., Sturk A., Nieuwland R. |
| |
|
CELL-MATRIX ADHESION IN VASCULAR DEVELOPMENT
|
| Hynes R.O. |
| |
|
CELLULAR FUNCTIONS OF APC
|
| Riewald M. |
| |
|
CERAMIDE KINASE/CERAMIDE 1-PHOSPHATE IS AN IMPORTANT REGULATOR ON AORTIC VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
|
| Kim T., Lim Y., Han H., Jin Y., Yoo H., Igarashi Y., Yun Y. |
| |
|
CEREBRAL THROMBOSIS ASSOCIATED WITH HETEROZYGOUS FV LEIDEN MUTATION AND HIGH LIPOPROTEIN A LEVEL IN A GIRL WITH FACTOR XIII DEFICIENCY
|
| Akbalik M., Duru F., Fisgin T., Tasdemir H., Incesu L., Albayrak D., Ozyurek H. |
| |
|
CEREBROVASCULAR THROMBOSIS DURING ESTROPROGESTINIC THERAPY IN A YOUNG WOMAN
|
| Durante C., Steffan A. |
| |
|
CERTIFY, A PHASE III STUDY COMPARING CERTOPARIN WITH UNFRACTIONATED HEPARIN IN ELDERLY, ACUTELY ILL MEDICAL PATIENTS
|
| Riess H.B., Sieder C., Schellong S., Haas S., Tebbe U., Gerlach H., Adams J. |
| |
|
CHALLENGES IN DEFINING TYPE 2M VON WILLEBRAND DISEASE: RESULTS FROM A CANADIAN COHORT STUDY
|
| Notley C., Lab L., Walker I., Poon M., Hcdc A., Rapson D., Lillicrap D., James P.D. |
| |
|
CHANGES IN HAEMOSTATIC FACTORS DURING AND AFTER LIVER TRANSPLANTATION IN CHILDREN
|
| Monagle P., Ignjatovic V., Teo S., Bhat R., Hardikar W., Jones B. |
| |
|
CHANGES IN PLATELET HAEMOSTASIS IN PATIENTS WITH ACUTE ACETIC ACID POISONING
|
| Rutskina E.A., Govorin A.V., Vitkovsky Y.A., Solpov A.V., Sokolova N.A., Boiko E.V., Zherebtsova S.V., Khludneva I.D. |
| |
|
CHANGES IN THROMBIN GENERATION KINETICS FOLLOWING HEMORRHAGIC SHOCK AND RESUSCITATION IN PIGS
|
| Martini W.Z., Pusateri A.E., Colvin S., Hess J.R., Holcomb J.B. |
| |
|
CHANGES OF INFLAMMATORY MARKERS DURING FOLLOW-UP OF PATIENTS WITH HEART FAILURE UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY
|
| Michelucci A., Sofi F., Gori A., Ricciardi G., Pieragnoli P., Lenti M., Cesari F., Abdullahi Said A., Abbate R., Gensini G. |
| |
|
CHANGES OF THE PLASMA LEVELS OF PLATELET AND ENDOTHELIAL MICROPARTICLES IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND ANTIHOSPHOLIPID SYNDROME
|
| Oh D., Jang M.M.J., Kang M.M.S., Lee S.S.J., Lee Y.Y.G., Oh S.S.Y., Chong S.S.Y., Bang S.S.M., Park S.S., Yun-Choi H.H.S. |
| |
|
CHANGES OF TISSUE FACTOR PATHWAY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
|
| Wang R., Wen B., Ma Y., Pen P., Li H., Zhong D., Li L. |
| |
|
CHAOTIC ADVECTION IN STENOSED ARTERIES
|
| Károlyi G., Schelin A., Grebogi C., Booth N.A., Moura A. |
| |
|
CHARACTERISATION OF AN INHIBITORY ANTIBODY FRAGMENT TO HUMAN TISSUE FACTOR
|
| Meiring M.S., Badenhorst P.N. |
| |
|
CHARACTERISATION OF ASE-LIKE ELEMENTS IN THE HUMAN PROTEIN Z GENE PROMOTER
|
| Ben-Hasan M., Winship P.R., Dalton C.F., Hall A.J. |
| |
|
CHARACTERISATION OF PREDICTED OESTROGEN RESPONSE ELEMENTS IN THE ITGA2 GENE PROMOTER
|
| Al-Zahrani F.M., Daly M.E., Winship P.R. |
| |
|
CHARACTERISATION OF RZPI PRODUCED IN ESCHERICHIA COLI
|
| Young L.K., Browett P., Van de Water N., Ockelford P., Birch N., Coughlin P., Harper P., Horvath A. |
| |
|
CHARACTERISATION OF THE ACTIVE FORM OF THE NOVEL ORAL DIRECT THROMBIN INHIBITOR AZD0837 IN COAGULATION ASSAYS
|
| Mattsson C., Lundin A., Ulvinge J. |
| |
|
CHARACTERISATION OF THE MOLECULAR GENETIC DEFECTS UNDERLYING GLANZMANN'S THROMBASTHENIA IN JORDANIAN FAMILIES
|
| Al-Marwani A., Awidi A.A., Arikat M., Mefleh R., Makris M., Daly M.E. |
| |
|
CHARACTERISTIC FEATURES OF SOLUBLE FIBRIN (SF) AND SOLUBLE FIBRIN MONOMER COMPLEX (FMC) AS MEASURED BY IMMUNOASSAYS WITH IATRO SF AND AUTO LIAFM, RESPECTIVELY
|
| Seki Y., Kobayashi E., Fuse I., Aizawa Y. |
| |
|
CHARACTERIZATION OF A LARGE DELETION THAT LEADS TO CONGENITAL FACTOR XIII DEFICIENCY
|
| Otaki M., Inaba H., Shinozawa K., Tamura A., Fujita S., Suzuki T., Amano K., Fukutake K. |
| |
|
CHARACTERIZATION OF A NEW METHOD TO ASSESS PLATELET ACTIVATION AND ERYTHROCYTE LYSIS DURING EXPOSURE TO PATHOPHYSIOLOGICAL SHEAR STRESS
|
| Kermode J.C., Burgreen G.W., Zheng Q., Ladner T., Majumdar S. |
| |
|
CHARACTERIZATION OF A PENTAPEPTIDE THAT MODULATES PROTHROMBINASE ACTIVITY
|
| Bukys M.A., Kim P.Y., Nesheim M.E., Kalafatis M. |
| |
|
CHARACTERIZATION OF ADAMTS13/FXI COMPLEX FROM PLASMA AND QUANTITATION BY ELISA IN NORMAL DONORS AND TTP PATIENTS
|
| Greenfield R.S., Guinto E., Grafos N., Fryer H.J.L., Ranzurmal S. |
| |
|
CHARACTERIZATION OF COMMERCIALLY AVAILABLE VWF-CONTAINING FVIII CONCENTRATES BY VWF MULTIMER ANALYSIS
|
| Metzner H.J., Budde U., Albers M., Schulte S. |
| |
|
CHARACTERIZATION OF PAR-MEDIATED SIGNALING CAPACITY OF COAGULATION FACTOR X MUTANTS
|
| Monti M., Borensztajn K.S., Pinotti M., Canella A., Bellini T., Spek A.C., Bernardi F. |
| |
|
CHARACTERIZATION OF THE F11 ALTERNATIVE SPLICING PATTERN: IDENTIFICATION OF A NOVEL COAGULATION FXI ISOFORM
|
| Guella I., Asselta R., Rimoldi V., Tenchini M., Duga S. |
| |
|
CHARACTERIZATION OF THE INTERACTION BETWEEN VON WILLEBRAND FACTOR AND OSTEOPROTEGERIN
|
| Shahbazi S., Fribourg C., Lenting P.J., Terraube V., Cécile D.V., Christophe O.D. |
| |
|
CHARACTERIZATION OF THE ROLE OF PLATELET ADHESION MOLECULES IN A MURINE MODEL OF PHOTOSENSITIZER-INDUCED STROKE
|
| Frederix K., Chauhan A.K., Kisucka J., Spronk H.M.H., Wagner D.D., ten Cate H. |
| |
|
CHARACTERIZATION OF VASCULAR ENDOTHELIAL CELLS WITH NULL THROMBOXANE A2 SYNTHASE
|
| Lin S., Hsu J., Yu I., Lin S. |
| |
|
CHEMOANTICOAGULATION VERSUS CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): RESULTS OF THE INTERIM ANALYSIS OF THE FRAGEM TRIAL
|
| Maraveyas A., Holmes M., Lofts F., Wedgewood K., Gardiner E., Sgouros J. |
| |
|
CHEMOTHERAPY AFFECTS ACTIVATED PROTEIN C GENERATION TO A GREATER DEGREE IN NEWBORN THAN IN ADULT PLASMA
|
| Mewhort-Buist T., Patel S., Berry L.R., Chan A.K.C. |
| |
|
CHILDHOOD GERM CELL TUMOR PRECEDING BY CHRONIC LONGSTANDING DIC
|
| Alavi S., Arzanian M., Shamsian S., Mahmoodi H. |
| |
|
CHLAMYDIA PNEUMONIA INFECTION AND ITS RELATION TO LIPIDS AND INFLAMMATORY MARKERS IN FAMILIES WITH EARLY-ONSET CORONARY ARTERY DISEASE
|
| Rao V.S., Renuka K.S., Natesha B.K., Kanjilal S., Mukherjee M., Kakkar V.V. |
| |
|
CIRCADIAN VARIATION IN THE PLATELET RESPONSE AND THE EFFECT OF MELATONIN
|
| Murray A., James T.E.B., Chan D., Goodall A.H. |
| |
|
CIRCADIAN VARIATIONS IN COAGULATION AND FIBRINOLYTIC FACTORS AMONG FOUR STRAINS OF MICE
|
| Ohkura N., Oishi K., Sakata T., Kadota K., Atsumi G., Ishida N., Matsuda J., Horie S. |
| |
|
CIRCULATING ANGIOPOIETIN-2 IS A STRONG PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA
|
| Schliemann C., Bieker R., Thoennissen N.H., Gerss J., Liersch R., Kessler T., Buechner T., Berdel W.E., Mesters R.M. |
| |
|
CIRCULATING ANTIBODIES TO HEAT SHOCK PROTEINS AND THEIR ASSOCIATION WITH ATHEROTHROMBOTIC PHENOTYPES
|
| Rao V.S., Pratima R.S., Natesha B.K., Shanker J., Kanjilal S., Mukherjee M., Kakkar V.V. |
| |
|
CIRCULATING ENDOTHELIAL CELLS (CECS) AND PROGENITORS (CEPS) IN SEVERE HEMOPHILIACS WITH DIFFERENT CLINICAL PHENOTYPE
|
| Biguzzi E., Mancuso P., Franchi F., Calleri A., Saronni L., Raia V., Rabascio C., Santagostino E., Mancuso M., Bertolini F., Mannucci P. |
| |
|
CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND INFLAMMATION IN PATIENTS BEFORE AND AFTER CARDIAC SURGERY
|
| Cesari F., Caporale R., Marcucci R., Gori A., Capalbo A., Alamanni C., Spinelli A., Stefano P., Abbate R., Gensini G. |
| |
|
Circulating inactive human Matrix Gla Protein (ucMGP) as a biomarker for cardiovascular disease
|
| Cranenburg E.C.M., Brandenburg V., Koos R., Ketteler M., Vermeer C., Schurgers L.J. |
| |
|
CIRCULATING LEVELS OF ADHESION MOLECULES AND MARKERS OF ENDOTHELIAL DYSFUNCTION IN ACUTE INFLAMMATION INDUCED BY PROLONGED BRISK EXERCISE: RAPID ENDOTHELIAL RECOVERY AND POTENTIAL BENEFICIAL EFFECTS
|
| Bartzeliotou A., Margeli A., Tsironi M., Skenderi K., Bacoula C., Chrousos G., Papassotiriou I. |
| |
|
CIRCULATING MATRIX GLA PROTEIN: A POTENTIAL MARKER FOR VASCULAR COMPLICATIONS OF TYPE 2 DIABETES MELLITUS
|
| Spronk H.M.H., Hansen H.R., Schürgers L.J., Vermeer C., Reitsma P.H., ten Cate H. |
| |
|
CIRCULATING MICROPARTICLE (MP)-ASSOCIATED TISSUE FACTOR (TF) ACTIVITY AND THROMBOSIS IN CANCER PATIENTS
|
| Tesselaar M.E.T., Romijn F.P.H., van der Linden I.K., Bertina R.M., Osanto S. |
| |
|
CIRCULATING PLATELET-MONOCYTE COMPLEXES AS POTENTIAL BIOMARKERS OF THE OVERALL ATHEROSCLEROSIS LOAD IN MEN WITH AND WITHOUT KNOWN CORONARY ARTERY DISEASE
|
| Dotsenko O., Coady E., Byrd S., Wright A., Mayet J., Kooner J., Shore A., Schalkwijk C., Thom S., Chaturvedi N., Hughes A.D. |
| |
|
CIRCULATING PROPLATELETS IN HEALTHY SUBJECTS AND PATIENTS
|
| Buryachkovskaya L.I., Uchitel I.A., Sumarokov A.B., Popov E.G. |
| |
|
CIRCULATING P-SELECTIN AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM
|
| Kyrle P.A., Hron G., Eichinger S., Wagner O. |
| |
|
CISPLATIN INDUCES IN VITRO THROMBIN GENERATION VIA FORMATION OF PROCOAGULANT ENDOTHELIAL MICROPARTICLES
|
| Lechner D., Kollars M., Gleiss A., Eichinger S., Kyrle P.A., Weltermann A. |
| |
|
CLASSIFICATION OF FACTOR V-LEIDEN CARRIERS BY QUANTITATIVELY MEASURING ITS PROCOAGULANT ACTIVITY COMPARATIVELY TO THAT OF FACTOR V
|
| Vissac A.M., Peyrafitte M., Leroy-Matheron C., Amiral J.J. |
| |
|
CLEARANCE OF FACTOR VIIA (FVIIA) IN THE MOUSE IS NOT AFFECTED BY ALPHA 2-MACROGLOBULIN GENE DELETION OR ACTIVE-SITE BLOCKAGE OF FVIIA
|
| Steinoe A., Karpf D.M., Olsen E.H.N., Tranholm M., Petersen L.C., Stennicke H.R., Ezban M., Sorensen B.B. |
| |
|
CLEAVED HIGH MOLECULAR WEIGHT KININOGEN (HKA) STIMULATES EXPRESSION OF MONOCYTE TISSUE FACTOR (TF) DEPENDENT ON SECRETION OF CYTOKINES AND CHEMOKINES
|
| Khan M.M., Colman R.W. |
| |
|
CLEAVED KININOGEN INHIBITS ANGIOGENESIS BY TARGETING ENDOTHELIAL CAVEOLAE
|
| Colman R.W., Wu Y. |
| |
|
CLEC-2, A NOVEL PLATELET ACTIVATION RECEPTOR, IS INVOLVED IN PODOPLANIN-MEDIATED PLATELET ACTIVATION BY CANCER CELLS
|
| Suzuki-Inoue K., Kato Y., Inoue O., Kato Kaneko M., Mishima K., Yatomi Y., Ozaki Y. |
| |
|
CLINICAL AND BIOLOGICAL ASPECTS OF VON WILLEBRAND DISEASE IN ALGERIA
|
| Badereddine L., Baghli L., Benhadda B. |
| |
|
CLINICAL APPLICATION OF ACTIVATED RECOMBINANT HUMAN FACTOR ? IN CHINA
|
| Ye X., Feng Y. |
| |
|
CLINICAL APPLICATIONS OF A DIRECT GENOMIC PLATFORM FOR SNP DETECTION IN HUMAN DNA SAMPLES USING GOLD NANOPARTICLE PROBE TECHNOLOGY AND ENHANCED SIGNAL AMPLIFICATION
|
| Campbell S.A., Catania M., Patno T., Cork W. |
| |
|
CLINICAL APPROACH TO HEPARIN-INDUCED THROMBOCYTOPENIA
|
| Alberio L. |
| |
|
CLINICAL ASPECTS OF HEREDITARY AND ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
|
| Kremer Hovinga J.A. |
| |
|
CLINICAL AUDIT OF THROMBOEMBOLISM PROPHYLAXIS 3 YEARS AFTER THE 6TH ACCP REPORT IN A TERTIARY CARE HOSPITAL FROM CRDOBA, ARGENTINA
|
| Tabares A.H., Ballarino G.J., Benegas M., Cremona S.L., Casanegra A.I. |
| |
|
CLINICAL CHARACTERISTICS OF CANCER ASSOCIATED ACUTE VENOUS THROMBOEMBOLISM: FINDINGS FROM THE MASTER REGISTRY
|
| Imberti D., Agnelli G., Ageno W., Moia M., Palareti G., Pistelli R., Rossi R., Verso M. |
| |
|
CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN CHILDHOOD- EXPERIENCE FROM A SINGLE CENTRE
|
| Biss T.T., Brandao L.R., Chan A.K., Williams S. |
| |
|
CLINICAL DETERMINANTS OF PLATELET FUNCTION IN PATIENTS WITH CAD UNDERGOING CORONARY ANGIOGRAPHY AND TREATED BY DUAL ANTIPLATELET THERAPY
|
| Marcucci R., Paniccia R., Gori A., Romano E., Antonucci E., Poli S., Buonamici P., Antoniucci D., Abbate R., Gensini G. |
| |
|
CLINICAL DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA
|
| Hammond S., Langley K., Smith G., Lahoz C., Dale C., MacCallum P. |
| |
|
CLINICAL EFFICACY AND SAFETY OF A NOVEL HIGH-PURITY, DOUBLE VIRUS-INACTIVATED VWF/FVIII-CONCENTRATE IN THE TREATMENT OF VON WILLEBRAND DISEASE AN UPDATE ON THE CLINICAL PROGRAMME
|
| Windyga J., von Depka M., Walter O., Jansen M., Auerswald G. |
| |
|
CLINICAL EFFICACY AND SAFETY OF FONDAPARINUX IN PATIENTS WITH CONGESTIVE HEART FAILURE (CHF): A SUBANALYSIS OF THE RANDOMIZED ARTEMIS TRIAL
|
| Eikelboom J., Cohen A.T., Turpie A.G. |
| |
|
CLINICAL EFFICACY OF ANTI-VENOM TREATMENT IN PAPUAN NEW GUINEA SNAKE-BITE PATIENTS
|
| Summerhayes R., Ignjatovic V., Williams D., Winkel K., Solchenberger B., Monagle P. |
| |
|
CLINICAL EVALUATION OF A NEW QUANTITATIVE HIGHLY SENSITIVE D-DIMER ASSAY FOR EXCLUSION OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
|
| de Moerloose P., Palareti G., Aguilar C., Legnani C., Reber G., Peetz D. |
| |
|
CLINICAL EXPERIANCE WITH A RAPID SCREENING TEST FOR HEPARIN/PF4-ANTIBODIES
|
| Bergmann F., Bruns C., Gröning A. |
| |
|
CLINICAL EXPERIENCE WITH A FACTOR XI (FXI) CONCENTRATE
|
| Gascoigne E.W., Dash C.H., Gillanders K.R. |
| |
|
CLINICAL EXPERIENCE WITH A HIGH PURITY FACTOR IX CONCENTRATE IN YOUNG CHILDREN
|
| Lee J.M., Dash C.H., Matysiak M., Stasyshyn O., Drozdova V., Vilchevska K. |
| |
|
CLINICAL EXPERIENCE WITH FACTOR VIII/VON-WILLEBRAND-FACTOR CONCENTRATE HAEMATE P RESULTS ON EFFICACY AND SAFETY IN A SINGLE CENTRE REGISTRY
|
| Zotz R.B., Moeller N., Mandeliev A., Scharf R.E. |
| |
|
CLINICAL EXPERIENCE WITH PLATELET AGGREGATION TESTING FOR ASPIRIN AND CLOPIDOGREL
|
| Jang S., Murugesan G., Kottke-Marchant K. |
| |
|
CLINICAL FACTORS INFLUENCING RETURN TO NORMAL HEMOSTASIS AFTER STOPPING WARFARIN
|
| Schulman S., Elbazi R., O'Donnell M., Robinson M. |
| |
|
CLINICAL FACTORS INFLUENCING THE SENSITIVITY TO WARFARIN WHEN RESTARTED AFTER SURGERY
|
| Schulman S., el Bouazzaoui B., Eikelboom J.W., Zondag M. |
| |
|
CLINICAL FEATURES AND TREATMENT OUTCOMES OF INFANTS WITH IMMUNE THROMBOCYTOPENIC PURPURA
|
| Arjmandi Rafsanjani K. |
| |
|
CLINICAL MANAGEMENT USING LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) IN PREGNANT WOMEN WITH THROMBOPHILIA, THROMBOEMBOLIC DISEASE (DVT) OR THROMBOPHILIA-RELATED MATERNOPLACENTAL SYNDROME: EXPERIENCE IN ONE CENTER
|
| Santamaría A., Vila J., Marco A., Mateo J., Simó M., Fontcuberta J. |
| |
|
CLINICAL OUTCOMES DURING BEMIPARIN POST-MARKETING OBSERVATIONAL STUDIES ON PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
|
| Gómez-Outes A., Rocha E., Fontcuberta J., Martínez-González J., Prandoni P. |
| |
|
CLINICAL OUTCOMES OF POINT-OF-CARE INR MONITORING FOR ANTICOAGULATION IN PRIMARY CARE PRACTICE
|
| Creagh M.D., Mohsin M., Naseem A., Carson P. |
| |
|
CLINICAL PHENOTYPES AND FACTOR VII GENOTYPE IN CONGENITAL FACTOR VII DEFICIENCY
|
| Schved J.F., Giansily-Blaizot M. |
| |
|
CLINICAL PROBABILITY ASSESSMENT AND D-DIMER DETERMINATION IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: COMPARISON BETWEEN LOCAL D-DIMER METHOD AND CENTRALIZED ANALYSIS IN BATCH
|
| Elf J., Strandberg K., Nilsson C., Svensson P.J. |
| |
|
CLINICAL PROBABILITY ASSESSMENT AND D-DIMER DETERMINATION IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: COMPARISON BETWEEN LOCAL D-DIMER METHOD AND CENTRALIZED ANALYSIS IN BATCH
|
| Elf J., Strandberg K., Nilsson C., Svensson P.J. |
| |
|
CLINICAL PROFILE AND MOLECULAR BASIS OF GLANZMANN'S THROMBASTHENIA [GT] IN THE SULTANATE OF OMAN
|
| Albalushi T.M., Albalushi T.M., Alzadjali S., Shanmugaonkar M., Alhaddabi H., Pathare A., Raeburn S., Arinami T. |
| |
|
CLINICAL RELEVANCE AND TUMOR BIOLOGICAL ROLE OF THE UROKINASE RECEPTOR MRNA SPLICE VARIANT UPAR-DEL4/5 IN BREAST CANCER
|
| Kotzsch M., Sato S., Sieuwerts A., Grosser M., Meye A., Smid M., Baretton G., Luther T., Magdolen V., Foekens J. |
| |
|
CLINICAL RISK FACTORS AND 3 MONTHS OUTCOMES OF SYMPTOMATIC CALF VEIN THROMBOSIS: FINDINGS FROM THE OPTIMEV COHORT
|
| Galanaud J., Khau Van Kien A., Boubakri C., Pernod G., Boge G., Laroche J., Gris J., Quére I., Bosson J. |
| |
|
CLINICAL SIGNIFICANCE OF HMGB-1, SF AND PAI-1 AS A VITAL- PROGNOSIS MARKER
|
| Koga S., Tamimoto S., Yonemura M., Yamada S., Sakurai J. |
| |
|
CLINICAL SIGNIFICANCE OF MEAN PLATELETS VOLUME IN CORONARY ARTERY DISEASE
|
| Aref S., Goda T. |
| |
|
CLINICAL SIGNIFICANCE OF MEAN PLATELETS VOLUME IN CORONARY ARTERY DISEASE
|
| Aref S., Goda T. |
| |
|
CLINICAL SIGNIFICANCE OF MICROPARTICLES
|
| Pabinger I. |
| |
|
CLINICAL SIGNIFICANCE OF PLATELET-DERIVED MICROPARTICLE (PDMP) IN APS: PLASMA LEVELS OF PDMP WERE SIGNIFICANTLY ELEVATED IN APS PATIENTS WITH ARTERIAL THROMBOSES
|
| Yamazaki M., Kadohira Y., Maekawa M., Ontachi Y., Morishira E., Asakura H., Nakao S. |
| |
|
CLINICAL STUDY OF MULTI-LOCUS B-FIBRINOGEN GENE POLYMORPHISMS
|
| Fang W. |
| |
|
CLINICAL USE OF TEST OF LYMPHOCYTE-PLATELET ADHESION
|
| Kuznik B.I., Solpov A.V., Gergesova E.E., Goryayev N.I., Duysebekov M.M., Kergenskova J.G., Lyanova K.M., Pershikov S.V., Batayeva E.P., Galsanamzhilova H.N., Emelyanova A.N., Ilynykh L.V., Sidyakova E.V., Drakunov A.V., Topolyev I.R., Vitkovsky Y.A. |
| |
|
CLINICAL, GENETIC, FUNCTIONAL AND CONFORMATIONAL HETEROGENEITY OF CONGENITAL ANTITHROMBIN DEFICIENCY. RESULTS FROM 27 UNRELATED CASES
|
| Ordóñez A., Sánchez I., Miñano A., González-Conejero R., Hernández-Espinosa D., Aznar J., Alberca I., Gómez N., López F.M., de Cos C., Cano H., Navarro M., Gutierrez-Pimentel J.M., Marcos P., García-Malo D.M., Llamas P., Marín D.M., Lecumberri R., Sánchez-Blanco J.J., Zuazu I., Vicente V., Corral J. |
| |
|
CLINICALLY - IMPORTANT VENOUS THROMBOEMBOLISM (CIVTE) FOLLOWING ISOLATED LEG FRACTURES DISTAL TO THE KNEE: EPIDEMIOLOGY AND PREVENTION: THE D-KAF (DALTEPARIN IN KNEE TO ANKLE FRACTURE) TRIAL
|
| Selby R., Geerts W.H., Kreder H.J., Crowther M.A., Kaus L., Sealey F., Jay R., Kiss A. |
| |
|
CLINICALLY SUSPECTED ACUTE RECURRENT PULMONARY EMBOLISM: A DIAGNOSTIC CHALLENGE
|
| Nijkeuter M., Kwakkel-van Erp H.M., Sohne M., Tick L.W., Kruip M.J.H.M., Ullmann E.F., Kramer M.H.H., Buller H.R., Prins M.H., Leebeek F.W.G., Huisman M.V. |
| |
|
CLONING, ANALYSIS AND STRUCTURAL PREDICTION OF LOSAC, A NEW HEMOLIN FROM LONOMIA OBLIQUA
|
| Flores M.P.A., Ramos O.H.P., Chudzinski-Tavassi A.M. |
| |
|
CLOPIDOGREL NON-RESPONSIVENESS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS
|
| Snoep J.D., Hovens M.M.C., Eikenboom J.C.J., van der Bom J.G., Jukema J.W., Huisman M.V. |
| |
|
CLOPIDOGREL PRODUCES DISTINCT DOSE-RESPONSE RELATIONSHIPS FOR INHIBITION OF PLATELET AGGREGATION (IPA) AND ANTITHROMBOTIC EFFICACY MEASURED IN RATS AND RABBITS
|
| Ogletree M.L., Wong P.C., Schumacher W.A., Rehfuss R.P. |
| |
|
CLOPIDOGREL TREATMENT SIGNIFICANTLY DECREASES CIRCULATING ENDOTHELIAL CELL COUNT IN PATIENTS WITH STABLE ANGINA
|
| Vargova K., Toth-Zsamboki E., Gulacsi-Bardos P., Beres B.J., Kiss R.G., Preda I. |
| |
|
CLOPIDOGREL UNRESPONSIVENESS OVERCOME BY RELOADING: ASSESSEMENT BY PLATELET AGGREGOMETRY AND IMPACT-R [CONE AND PLATE(LET) ANALYZER]
|
| Matetzky S., Shenkman B., Hod H., Fefer P., Varon D., Savion N. |
| |
|
CLOT FORMATION AS TREATMENT METHOD FOR PATHOLOGICAL FOCUS: A MATHEMATICAL MODEL
|
| Khanin M.A., Tyurin K.V., Druzhinin A. |
| |
|
CLOT STRUCTURE MODIFICATION BY FONDAPARINUX AND CONSEQUENCE ON FIBRINOLYSIS: A NEW MECHANISM OF ANTITHROMBOTIC ACTIVITY
|
| Varin R., Mirshahi S.S., Mirshahi P., Kierzek G., Sebaoun D., Mishal Z., Vannier J.P., Borg J.Y., Simoneau G., Soria C., Soria J. |
| |
|
CLOTTING AND INFLAMMATION MARKERS WHEN INCLUDING RECOMBINANT ACTIVATED PROTEIN C (RAPC) IN SEPSIS THERAPY
|
| Klimovich L.G. |
| |
|
CLOTTING IN THE STREAM: NONTHROMBOCYTE PLASMA
|
| Savushkin A.V. |
| |
|
CLUSTERING OF SURFACE-BOUND BETA2-GLYCOPROTEIN I
|
| Matsumoto S., Hayashi A., Matsuura E., Suzuki K., Kato H., Takeya H. |
| |
|
COADMINISTRATION OF THE ORAL DIRECT THROMBIN INHIBITOR DABIGATRAN ETEXILATE AND DICLOFENAC HAS LITTLE IMPACT ON THE PHARMACOKINETICS OF EITHER DRUG
|
| Stangier J., Stähle H., Rathgen K., Reseski K., Körnicke T. |
| |
|
COADMINSTRATION OF THE ORAL DIRECT THROMBIN INHIBITOR DABIGATRAN ETEXILATE AND ATORVASTATIN HAS LITTLE IMPACT ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EITHER DRUG
|
| Stangier J., Stähle H., Rathgen K., Reseski K., Körnicke T. |
| |
|
COAGUCHEK XS IN COMPARISON TO BCS ANALYZER. RESULTS IN AN OUTPATIENT ANTICOAGULATION CLINIC, FOCUSED IN METAL VALVE DISEASE
|
| Tsoucala C., Kotsi P., Anastasopoulou I., Chanos A., Karafoulidou A. |
| |
|
COAGULANT PROPERTIES OF MICROPARTICLE-ASSOCIATED FUSION PRODUCTS OF FULL LENGTH AND ALTERNATIVELY SPLICED HUMAN TISSUE FACTOR WITH GREEN FLUORESCENT PROTEIN
|
| Böing A.N., Hau C.M., Sturk A., Nieuwland R. |
| |
|
COAGULATION ABNORMALITIES IN WOMEN WITH VERIFIED MENORRHAGIA IS IT TIME FOR INCLUSION OF COAGULATION SCREENING IN DIAGNOSTIC ALGORITHM?
|
| Simic S.M., Andjelkovic N., Djurdjevic P., Djukic A.L., Antovic J. |
| |
|
COAGULATION FACTOR VII LEVELS ARE MODULATED BY THE BIOLOGICAL CLOCK
|
| Pinotti M., Bertolucci C., Colognesi I., Frigato E., Pasquali V., Renzi P., Foa A., Bernardi F. |
| |
|
COAGULATION FACTOR VIIA VARIANTS WITH REDUCED SUSCEPTIBILITY TO INHIBITION BY ANTITHROMBIN III
|
| Larsen K.S., Olsen O.H., Stennicke H.R., Petersen L.C., Ostergaard H. |
| |
|
COAGULATION FACTOR XA INHIBITS CANCER CELL MIGRATION VIA LIMK1-MEDIATED COFILIN INACTIVATION
|
| Borensztajn K.S., Bijlsma M.F., Stiekema J., Reitsma P.H., Peppelenbosch M.P., Spek C.A. |
| |
|
COAGULATION FACTOR XI LEVELS AND THE LDL RECEPTOR-RELATED PROTEIN (LRP) GENOTYPE
|
| Marchetti G., Lunghi B., Legnani C., Cini M., Pinotti M., Palareti G., Bernardi F. |
| |
|
COAGULATION FACTOR XII MISSENSE MUTATIONS (T309K, T309R) IN HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR
|
| Dewald G., Bork K. |
| |
|
COAGULATION FACTORS AND THE PROTEIN C SYSTEM AS DETERMINANTS OF THROMBIN GENERATION
|
| Dielis A.W.J.H., Castoldi E., Spronk H.M.H., van Oerle R., Hamulyák K., Rosing J., ten Cate H. |
| |
|
COAGULATION FACTORS IX - XIII AND RISK OF FUTURE VENOUS THROMBOSIS: THE LONGITUDINAL INVESTIGATION OF THROMBOEMBOLISM ETIOLOGY (LITE)
|
| Cushman M., O'Meara E., Heckbert S.R., Rosamond W., Folsom A.R. |
| |
|
COAGULATION PARAMETERS IN AMNIOTIC FLUID DURING HUMAN PREGNANCY ROLE OF TF AND TFPI
|
| Sarig G., Drugan A., Klil A., Chap-Marshak D., Brenner B. |
| |
|
COAGULATION PARAMETERS OF THE ISTH OVERT DIC SCORE: FIRST, THEIR DISTRIBUTION
|
| Leyte A., Hogenboom S., Cramer B.G., Wester J.P.J., Bosman R.J., Oudemans-van Straaten H.M., van der Spoel H.I., Terpstra W.E., Treskes M., Zandstra D.F. |
| |
|
COAGULATION STUDIES IN PATIENTS PRESENTING WITH HYPOTHERMIA
|
| Donald M., Morrison W., Savory M., Kerr R. |
| |
|
COFILIN, BUT NOT ADF, IS ESSENTIAL IN PLATELET FORMATION IN VIVO
|
| Bender M., Elvers M., Varga-Szabo D., Gurniak C., Witke W., Nieswandt B. |
| |
|
COINHERITANCE OF FV-LEIDEN MUTATION AND FV-HR2
|
| Makris M.P., Papamichos S.I., Kanidis A., Makris P.E. |
| |
|
COLLAGEN AFFINITY TO VON WILLEBRAND FACTOR CONTAINED IN A THERAPEUTIC FVIII/VWF CONCENTRATE EVALUATED BY SURFACE PLASMON RESONANCE
|
| Grancha S., Jorquera J.I. |
| |
|
COLLAGEN PROMOTES SUSTAINED GPVI SIGNALING IN PLATELETS AND CELL LINES
|
| Tomlinson M.G., Calaminus S.D., Berlanga O., Auger J.M., Bori-Sanz T., Watson S.P. |
| |
|
COMBINATION THERAPY OF A PORCINE BONE TRAUMA FOLLOWING A DILUTIONAL COAGULOPATHY BY PROTHROMBIN COMPLEX CONCENTRATE (PCC) AND FIBRINOGEN
|
| Dickneite G. |
| |
|
COMBINED ANTIPLATELET AND ANTICOAGULANT THERAPY: CLINICAL BENEFITS AND RISKS
|
| Eikelboom J.W., Hirsh J. |
| |
|
COMBINED EFFECTS OF RFVIIA AND RFXIII ON CLOT FORMATION AND STABILITY IN PLASMA AND BLOOD FROM NORMAL DONORS AND FROM THROMBOCYTOPENIC PATIENTS
|
| Kjalke M., Viuff D., Petersen L.C., Jacobsen N., Olsen E.H.N., Rojkjaer R., Johansson P.I. |
| |
|
COMBINED FACTOR V AND FACTOR VIII DEFICIENCY IN INDIA - A SERIES OF 31 PATIENTS
|
| Viswabandya A., Nair S.C., Baidya S., Mathews V., George B., Chandy M., Srivastava A. |
| |
|
COMBINED FACTOR V AND FACTOR VIII DEFICIENCY: MUTATION ANALYSIS AND ETHNICAL BACKGROUND OF FIVE PATIENTS
|
| Sittinger K., Geisen C., Watzka M., Ivaskevicius V., Heller C., Kappert G., Kadar J.G., Zieger B., Laws H.J., Seifried E., Oldenburg J. |
| |
|
COMBINED FACTOR V AND VIII DEFICIENCY, A LARGE GROUP FROM IRAN
|
| Baghaipour M.R., Sadeghian K., Rastegar Lari G., Naghib A. |
| |
|
COMBINED POLYMORPHISM MARKERS FOR CARRIER AND PRENATAL DIAGNOSIS OF HAEMOPHILIA IN CHINA
|
| Lu Y., Wang X., Ding Q., Wang H. |
| |
|
COMBINING 4T'S PRE-TEST CLINICAL SCORE AND ID-PAGIA HEPARIN/PF4 TEST TO EXCLUDE HEPARIN INDUCED THROMBOCYTOPENIA (HIT)
|
| Low J., Austin S., Bryant A., Joseph J. |
| |
|
COMBINING RIVAROXABAN WITH ACETYLSALICYLIC ACID INCREASES ANTITHROMBOTIC POTENCY WITHOUT AFFECTING BLEEDING TIMES IN ANIMAL MODELS
|
| Perzborn E., Fischer E., Lange U. |
| |
|
COMMON GENE MUTATIONS AND VENOUS THROMBOEMBOLISM: DISTINCT ROLES IN DIFFERENT CLINICAL SETTINGS
|
| Colaizzo D., Vergura P., Guardascione M.A., Cappucci F., Tiscia G.L., Iannaccone L., Grandone E., Cocomazzi N., Amitrano L., Margaglione M. |
| |
|
Common thrombophilias in 85 Indian patients with arterial thrombosis
|
| Mishra M.N., Kalra R., Rohatgi S. |
| |
|
COMPARATIVE "IN VITRO" CHARACTERIZATION OF DIFFERENT PROTHROMBIN COMPLEX CONCENTRATES
|
| Bernardi M.E., Bermudez M.C., Martinez M., Guglielmone H., Farias F., Vitali M.S. |
| |
|
COMPARATIVE STUDY OF THE EFFECTS OF NATURAL HONEY, SESAME OIL, AND SOY MILK CONSUMPTION ON BLOOD LEVEL OF LIPID PEROXIDATION AND TOTAL PHENOLIC COMPOUNDS
|
| Settasatian C., Settasatian N., Teerajetgul Y., Sirijaichingkul S. |
| |
|
COMPARATIVE STUDY ON APTT REAGENTS
|
| Stroobants A.K., van den Dool E. |
| |
|
COMPARATIVE STUDY ON THE ANTICOAGULANT EFFECTS OF UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS, LOWER LOW MOLECULAR WEIGHT HEPARINS AND PENTASACCAHRIDE AS MEASURED BY WHOLE BLOOD ACT, ANTI-XA AND A NEWLY DEVELOPED PROTHROMBINASE INDUCED CLOTTING TIME
|
| Wahi R., Hoppensteadt D., Tobu M., Iqbal O., Walenga J.M., Demir M., Fareed D., Fareed J. |
| |
|
COMPARISON BETWEEN CONVENTIONAL AND AUTOMATED METHODS OF RISTOCETIN COFACTOR ACTIVITY AND VON WILLEBRAND FACTOR ANTIGEN
|
| Ouviña S.M., Da Representacao S., Guzman A., Dourisboure R., Maneyro A., Palmer L., Meschengieser S.S., Ferro A.M. |
| |
|
COMPARISON OF A HEPARIN-PLATELET FACTOR 4 (PF4)-ELISA FOR IGG, IGM AND IGA AND THE HEPARIN-INDUCED PLATELET ACTIVATION ASSAY (HIPA) WITH A HEPARIN-PF4-ELISA FOR IGG
|
| Luxembourg B., Adam M., Woodhams B., Maertens B., Lindhoff-Last E. |
| |
|
COMPARISON OF A NEW CARTRIDGE* FOR THE PFA-100 WITH OTHER PLATELET FUNCTION ASSAYS FOR MEASURING THE EFFECT OF CLOPIDOGREL THERAPY IN CARDIOVASCULAR PATIENTS
|
| van Werkum J.W., ten Berg J.M., Rechner A.R., de Haan J., Hackeng C.M. |
| |
|
COMPARISON OF AN IMMUNO-TURBIDOMETRIC D-DIMER METHOD WITH AN ESTABLISHED ENZYME-LINKED FLUORESCENT D-DIMER FOR THE EXCLUSION OF VENOUS THROMBOEMBOLISM
|
| Sukhu K., Beavis J., Baker P., Keeling D.M. |
| |
|
COMPARISON OF ANTIPLATELET AND ANTITHROMBOTIC EFFECTS OF PRASUGREL AND AZD6140
|
| Ogawa T., Isobe C., Kakusaka M., Yokouchi Y., Niitsu Y., Jakubowski J.A., Sugidachi A., Asai F. |
| |
|
COMPARISON OF ANTITHROMBOTIC PROPERTIES OF A DIRECT FXA INHIBITOR, DU-176B, WITH AN ANTITHROMBIN DEPENDENT FXA INHIBITOR, FONDAPARINUX, IN A CAPILLARY PERFUSION CHAMBER THROMBOSIS MODEL
|
| Shibano T., Tsuji N., Fukuda T., Morishima Y. |
| |
|
COMPARISON OF COAGUCHEK S, XS AND LABORATORY INRS
|
| Williams V.K., Griffiths A.B.M. |
| |
|
COMPARISON OF DIFFERENT METHODS FOR ISOLATION AND STORAGE OF MICROPARTICLES FROM HUMAN BLOOD
|
| Weber H., Kollars M., Kyrle P.A., Weltermann A. |
| |
|
COMPARISON OF EFFICACY AND SAFETY OF INTRAVENOUS AND INTRA-ARTERIAL THROMBOLYSIS IN ACUTE ISCHEMIC STROKE
|
| He Y., Yin M., Fu Z., Qiu L., Ma L. |
| |
|
COMPARISON OF ENDOTHELIAL CELL PROTEIN C RECEPTOR (EPCR) MRNA FORMS IN MONOCYTES AND HUVEC
|
| Saposnik B., Gaussem P., Lokajczyk A., Vedie B., Emmerich J., Aiach M., Gandrille S. |
| |
|
COMPARISON OF FIX CONCENTRATES BY CALIBRATED AUTOMATED THROMBIN GENERATION ASSAY (CAT)
|
| van Veen J.J., Gray E., Hogwood J., Gatt A., Cooper P.C., Kitchen S., Makris M. |
| |
|
COMPARISON OF FOUR CLINICAL PREDICTION MODELS IN PATIENTS WITH SUSPECTED PULMONARY EMBOLISM
|
| Pengo M., Pengo V., Bernardi E., Prandoni P. |
| |
|
COMPARISON OF HUMAN RFVIII AND MURINE RFVIII IN A STANDARDIZED FVIII DEPENDENT BLEED MODEL IN FVIII -/- MICE
|
| Jesmok G.J., Cui Z., Canivel D., Lollar P., Parker E.T., Landskroner K.A. |
| |
|
COMPARISON OF IMPEDANCE WHOLE BLOOD AGGREGATION AND OPTICAL PLATELET-RICH PLASMA AGGREGATION TO MEASURE THE ANTIPLATELET EFFECT OF ASPIRIN IN HEALTHY CONTROLS AND IN PATIENTS WITH PERIPHERAL ARTERY DISEASE (PAD)
|
| Tran H.A., Anand S.S., Ginsberg J.S., Weitz J.I., Johnston M., Eikelboom J.W. |
| |
|
COMPARISON OF INTERNATIONAL NORMALIZED RATIOS (INRS) DETERMINED BY INRATIO AND COAGU-CHEK XS WITH PLASMA-BASED LABORATORY INR: INFLUENCE OF LUPUS ANTICOAGULANTS
|
| Engelsen J., Dalsgaard Nielsen J. |
| |
|
COMPARISON OF LABORATORY DETECTION METHODS OF ASPIRIN RESISTANCE IN CARDIOVASCULAR DISEASE PATIENTS
|
| Han J., Kim K., Ko R., Woo K., Kim M. |
| |
|
COMPARISON OF PEGYLATED LIPOSOMAL FVIII INFUSION RATES IN HEMOPHILIA A
|
| Martinowitz U., Lelazari S., Luboshitz J., Lubezki A., Spira J. |
| |
|
COMPARISON OF PIFA RAPID ASSAY WITH ELISA TO DETECT HEPARIN/PLATELET FACTOR 4 (HPF4) ANTIBODIES
|
| Castellone D.D., Peerschke E.E.I.B. |
| |
|
COMPARISON OF PRE-TEST PROBABILITY SCORES TO COMMERCIAL ASSAYS FOR MEASURING ANTIBODIES ASSOCIATED WITH HEPARIN-INDUCED THROMBOCYTOPENIA
|
| Gosselin R.C., Dager W.E., Janatpour K.A., Lee A., Owings J.T. |
| |
|
COMPARISON OF SINGLE AND SEVEN-DAY ASPIRIN PLATELET RESPONSE REVEALS DOSAGE EFFECT AT 81 AND 325 MG
|
| McGlasson D.L., Fritsma G.A. |
| |
|
COMPARISON OF SYSTEMIC TISSUE PLASMINOGEN ACTIVATOR FOR VENOUS THROMBI AND ARTERIAL THROMBI IN CHILDREN
|
| Traivaree C., Brandao L., Chan A., Williams S. |
| |
|
COMPARISON OF THE 30-DAY INCIDENCE OF ISCHEMIC STROKE AND BLEEDING AFTER MAJOR SURGERY IN PATIENTS WITH AND WITHOUT ATRIAL FIBRILLATION (AF)
|
| White R.H., Kaatz S., Douketis J., Zhou H., Gage B.F. |
| |
|
COMPARISON OF THE ASSERACHROM VON WILLEBRAND FACTOR ANTIGEN ASSAY AND THE LIATEST VWF ASSAY AUTOMATED ON THE AMAX 200 COAGULATION ANALYZER IN HUMAN AND CANINE PLASMA SAMPLES
|
| Lauzon M., Angeloni F., McEwen N., McGrath J., Johnston M. |
| |
|
COMPARISON OF THE ASSOCIATIONS BETWEEN HAEMOSTATIC AND INFLAMMATORY VARIABLES AND CHD RISK: FLETCHER CHALLENGE STUDY
|
| Lowe G.D.O., Woodward M., Rumley A., Welsh P., MacMahon S., Danesh J. |
| |
|
COMPARISON OF THE EFFECTS OF THE P2Y14 RECEPTOR AGONIST UDP-GLUCOSE AND THE EP3 RECEPTOR AGONIST SULPROSTONE ON PLATELET FUNCTION
|
| Wijeyeratne Y.D., White A.E., Ralevic V., Heptinstall S. |
| |
|
COMPARISON OF THE IMMUNOGENICITY OF DIFFERENT THERAPEUTIC PREPARATIONS OF HUMAN FACTOR VIII IN THE MURINE MODEL OF HEMOPHILIA A
|
| Delignat S., Dasgupta S., Navarrete A., Kaveri S.V., Tellier Z., Chtourou S., Lacroix-Desmazes S. |
| |
|
COMPARISON OF THE INCIDENCE OF RECURRENT VENOUS THROMBOEMBOLISM AFTER PREGNANCY-ASSOCIATED VTE VERSUS IDIOPATHIC VTE
|
| White R.H., Ginsberg J., Zhou H. |
| |
|
COMPARISON OF THE REVISED GENEVA RULE WITH WELLS RULE FOR ASSESSING CLINICAL PROBABILITY OF PULMONARY EMBOLISM
|
| Klok F.A., Kruijswijk E., Spaan J., Nijkeuter M., Perrier A., Le Gal G., Huisman M.V. |
| |
|
COMPARISON OF THREE DIFFERENT TAFI ASSAYS IN PATIENTS WITH ACUTE CORONARY SYNDROME
|
| Skeppholm M., Wallén H., Malmqvist K., Kallner A., Antovic J.P. |
| |
|
COMPARISON OF THREE METHODOLOGIES TO ASSAY D-DIMER LEVELS IN SURGICAL PATIENTS: D DIMER ON MINIVIDAS VS. TINA-QUANT ON MODULAR P VS. TINA-QUANT ON BEHRING COAGULATION SYSTEM - A CALL FOR STANDARDISATION IN D-DIMER TESTING
|
| Bestmann L., Dindo D., Breitenstein S., Kaplan V., Kempf G., Asmis L.M. |
| |
|
COMPARISON OF THROMBIN GENERATION AND FVIII LEVEL MEASUREMENTS IN HAEMOPHILIA PATIENTS AFTER RECOMBINANT FACTOR VIII TREATMENT
|
| Dielis A.W.J.H., Balliel W.M.R., van Oerle R., Hermens W.T., ten Cate H., Hamulyák K. |
| |
|
COMPARISON OF THROMBIN GENERATION WITH MODIFIED THROMBOELASTOMETRY IN HAEMOPHILIA A
|
| van Veen J.J., Gatt A., Bowyer A.E., Cooper P.C., Kitchen S., Makris M. |
| |
|
COMPARISON OF TWO ANTI-XA ASSAYS USING A SINGLE CALIBRATION CURVE FOR MONITORING HEPARIN ANTICOAGULATION
|
| McGlasson D.L., Fritsma G.A. |
| |
|
COMPARISON OF TWO ASSAYS FOR THE MEASUREMENT OF URINARY 11-DEHYDRO THROMBOXANE B2
|
| Johnston M., Wentworth S., Lauzon M., Eikelboom J.W. |
| |
|
COMPARISON OF TWO ASSAYS FOR THE MEASUREMENT OF URINARY 11-DEHYRO THROMBOXANE B2
|
| Gilmore G., Thom J., Rankin J., Yong G., Eikelboom J.W. |
| |
|
COMPARISON OF TWO WHOLE BLOOD PLATELET FUNCTION ASSAYS: PFA-100 AND A NEW MULTIPLE ELECTRODE AGGREGOMETRY (MULTIPLATE) FOR CONTROL OF ASPIRIN AND/OR CLOPIDOGREL EFFECT
|
| Martin-Toutain I., Collet J., Genevee M., Couty M., Montalescot G., Ankri A. |
| |
|
COMPETITION BETWEEN REVERSIBLE AND IRREVERSIBLE P2Y12 ANTAGONISTS AND ITS INFLUENCE ON ADP-MEDIATED PLATELET ACTIVATION
|
| Dovlatova N.L., Jakubowski J.A., Sugidachi A., Heptinstall S. |
| |
|
COMPLEMENT C3 IS A PLASMA CLOT COMPONENT AND INFLUENCES CLOT LYSIS
|
| Carter A.M., Somani R., Howes J., Shore A., Standeven K.F., Grant P.J. |
| |
|
COMPLEX MECHANISMS CONTROLLING THE THROMBIN-INDUCED GENERATION OF ENDOTHELIAL MICROPARTICLES
|
| Simoncini S., Sapet C., Robert S., Sampol J., Nguyen C., Dignat-George F., Anfosso F. |
| |
|
COMPONENTS OF VARIABILITY OF D DIMER MEASUREMENT CLOSE TO THE CUT-OFF VALUE
|
| Guerrero F., Sie P., Camoin L., de Prost D., Le Querrec A., Freyburger G. |
| |
|
COMPRESSION BANDAGING IN THE ACUTE PHASE OF DEEP-VEIN THROMBOSIS IN RELATION TO THE POST-THROMBOTIC SYNDROME
|
| Roumen-Klappe E.M., den Heijer M., van Rossum J., Wollersheim H., van der Vleuten C., Thien T., Janssen M.C.H. |
| |
|
CONCURRENT RELEASE OF NATIVE CONFORMATION REACTIVE CENTER LOOP AND HELIX D STRAND 2A STRUCTURAL CONSTRAINTS FULLY ACTIVATES ANTITHROMBIN III IN THE ABSENCE OF HEPARIN
|
| dela Cruz R.C., Lu A., Bock S.C. |
| |
|
CONFIRMATION OF EFFICACY, SAFETY AND COST EFFECTIVENESS OF FRAXIPARINE FORTE IN THE OUTPATIENT TREATMENT OF DEEP VENOUS THROMBOSIS
|
| Maly J., Dulicek P., Pecka M., Vodickova L., Maly R. |
| |
|
CONFORMATION-SPECIFIC BLOCKADE OF THE INTEGRIN GPIIB/IIIA): IN VITRO AND IN VIVO RESULTS DEMONSTRATING A SELECTIVE PLATELET BLOCKADE WITH LESS ADVERSE EFFECTS
|
| Schwarz M., Meade G., Stoll P., Bassler N., Bode C., Peter K. |
| |
|
CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA (CAMT): CLINICAL AND BIOLOGICAL CHARACTERIZATION OF FIVE NEW MUTATIONS
|
| Noris P., Savoia A., Dufour C., Locatelli F., Di Bari F., Ambaglio C., Rosti V., Zecca M., Ferrari S., Corcione A., Di Stazio M., Seri M., Balduini C. |
| |
|
CONSIDERATION OF MODIFIED CUT-OFFS FOR ANTHROPOMETRIC VARIABLES IN DEFINING METABOLIC SYNDROME AMONG ASIAN INDIANS WITH CORONARY ARTERY DISEASE (CAD)
|
| Kanjilal S., Shanker J., Rao V.S., Natesha B.K., Mukherjee M., Kakkar V.V. |
| |
|
CONSTITUTIVELY ACTIVE OR INACTIVE I DOMAINS AS PROBES FOR INTEGRIN BINDING TO COLLAGEN
|
| Hamaia S.W., Allcott N., Peachey A.R., Fernandez R., Raynal N., Farndale R.W. |
| |
|
CONSTRUCTION AND IDENTIFICATION OF LENTIVIRUS - MEDIATED RNAI VECTORS CONTAINING HUMAN TISSUE FACTOR
|
| Xiong S.L., Bao J., Zheng L., Zeng F.Y., Qiu Y.R., Wang Q. |
| |
|
CONTACT-DEPENDENT INTERACTIONS THAT AFFECT THROMBUS GROWTH AND STABILITY
|
| Brass L.F. |
| |
|
CONTINUOUS INFUSION OF A HIGH PURITY FACTOR IX (HPFIX) CONCENTRATE IN SURGERY
|
| Dash C.H., Gascoigne E.W., Smith L., Gillanders K.R. |
| |
|
CONTINUOUS INFUSION OF VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE IN PATIENTS WITH CONGENITAL VON WILLEBRAND DISEASE
|
| Suzuki T., Amano K., Kagawa K., Tsujikawa A., Ogata K., Uchida T., Koh A., Otaki M., Kato H., Seita I., Tamura A., Fujita S., Takahashi Y., Tanaka A., Koshihara K., Nishida Y., Yamamoto Y., Fukutake K. |
| |
|
CONTRAINDICATIONS TO ANTICOAGULANTS ARE COMMON IN PATIENTS REQUIRING VENOUS THROMBOEMBOLISM PROPHYLAXIS
|
| Gibbs H., Collins R., Gibbs J. |
| |
|
CONTRIBUTION OF ALPHA-FIBRINOGEN A312 ALLELE TO DECREASED THROMBIN GENERATION IN PATIENTS SCHEDULED FOR CORONARY ARTERY BYPASS GRAFTING SURGERY
|
| Stepien E., Branicka A., Toton J., Wiek I., Kapelak B., Bozek M., Undas A. |
| |
|
CONTRIBUTION OF ASP334 AND TYR335 OF FACTOR VA TO PROTHROMBINASE FUNCTION
|
| Barhoover M.A., Orban T., Beck D.O., Kalafatis M. |
| |
|
CONTRIBUTION OF C46T MUTATION IN F12 GENE TO THROMBOTIC RISK IN THROMBOPHILIC FAMILIES WITH FACTOR V LEIDEN MUTATION
|
| Tirado I., Soria J., Oliver A., Mateo J., Souto J., Companys E., Coll I., Santamaria A., Fontcuberta J. |
| |
|
CONTRIBUTION OF CHROMATOGRAPHY STEPS IN PRION REMOVAL IN PLASMA-DERIVED PRODUCT MANUFACTURING
|
| Arrabal S., Tellier M., Porte P., Kimmel-Jehan C., Chtourou S., Flan B. |
| |
|
CONTRIBUTION OF FACTOR XA (FXA) IN THE THREE DIMENSIONAL GROWTH OF PLATELET THROMBI FORMED ON COLLAGEN FIBRILS UNDER BLOOD FLOW CONDITIONS
|
| Tamura N., Kitajima I., Ishida H., Goto S. |
| |
|
CONTRIBUTION OF GENETIC ANALYSIS FOR DIAGNOSIS OF VON WILLEBRAND DISEASE TYPE 2B
|
| Vinciguerra C., Victor M., Rugeri L., Meunier S., Grenier C., Fretigny M., Negrier C. |
| |
|
CONTRIBUTION OF INDIVIDUAL PURINOCEPTOR SUBTYPES TO PLATELET ACTIVATION BY VON WILLEBRAND FACTOR UNDER STATIC CONDITIONS
|
| Kermode J.C., Zheng Q. |
| |
|
CONTRIBUTION OF NATURAL ANTICOAGULANT AND FIBRINOLYTIC FACTORS IN MODULATING THE CLINICAL SEVERITY OF HEMOPHILIA PATIENTS
|
| Shetty S., Vora S., Kulkarni B., Mota L., Vijapurkar M., Quadros L., Ghosh K. |
| |
|
CONTRIBUTION OF ROTATION THROMBOELASTOGRAPHY (RT) IN PERIOPERATIVE MANAGEMENT OF PATIENTS WITH GLAZMANN'S THROMBASTHENIA (GT)
|
| Kouramba A., Anastasopoulou I., Laiou E., Kotsi P., Tsoucala C., Katsarou O., Karafoulidou A. |
| |
|
CONTRIBUTIONS OF COLLAGEN AND GLYCOPROTEIN VI SIGNALLING IN THE INTRINSIC PATHWAY OF COAGULATION
|
| van der Meijden P.E.J., Munnix I.C.A., Kuijpers M.J.E., Auger J.M., Watson S.P., Heemskerk J.W.M. |
| |
|
CONTROL SHEDDING OF GPIB-IX-V AND GPVI BY ADAM FAMILY METALLOPROTEINASES
|
| Shen Y., Gardiner E.E., Karunakaran D., Andrews R.K., Berndt M.C. |
| |
|
CONTROVERSIAL ISSUES REGARDING THROMBOPROPHYLAXIS IN SURGICAL PATIENTS
|
| Dahl O.E. |
| |
|
CONTROVERSIES IN THE TREATMENT OF THE ANTIPHOSPHOLIPID SYNDROME
|
| Schulman S. |
| |
|
CONVENIENCE OF THE NEW LONG-ACTING ANTICOAGULANT IDRAPARINUX (IDRA) VERSUS VITAMIN K ANTAGONIST (VKA) IN PATIENTS WITH DEEP VENOUS THROMBOSIS (DVT)
|
| Prins M.H., Leguet P., Gilet H., Roborel de Climens A. |
| |
|
COORDINATED ACTION OF GPVI AND FCRGAMMA CYTOPLASMIC DOMAINS IN SIGNALLING
|
| Minullina I., Dumont B., Loyau S., Pfirsch S., Monteiro R.C., Jandrot-Perrus M. |
| |
|
CORN TRYPSIN INHIBITOR AND THE CONTACT FACTOR PATHWAY IN THE THROMBIN GENERATION TEST (TGT)
|
| Hogwood J., Gray E. |
| |
|
CORONARY ARTERY BYPASS GRAFTING (CABG) IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
|
| Jubelirer S.J., Mousa L., Reddy U.P., Mir M., Welch C.A. |
| |
|
CORONARY ARTERY DISEASE (CAD): LACK OF ASSOCIATION BETWEEN APOB/APOA-I RATIO AND ATHEROMATOSIS EXTENT
|
| Lima L.M., Carvalho M.G., Neto C.P.F., Garcia J.C.F., Sousa M.O. |
| |
|
CORONARY ARTERY IN-STENT STENOSIS PERSISTS DESPITE INHIBITION OF THE VON WILLEBRAND FACTOR-COLLAGEN INTERACTION IN BABOONS
|
| De Meyer S.F., Staelens S., Badenhorst P.N., Pieters H., Lamprecht S., Roodt J., Janssens S., Meiring M., Vanhoorelbeke K., Bruwer A., Brown S., Deckmyn H. |
| |
|
CORONARY INSTENT RESTENOSIS OF DRUG-ELUTING STENTS IS ASSOCIATED WITH SERUM LEVELS OF MMP-9
|
| Katsaros K.M., Speidl W.S., Kastl S.P., Scheinig D., Huber K., Glogar D., Maurer G., Wojta J., Christ G. |
| |
|
CORRECTION HAEMOSTASIOLOGIC AND RHEOLOGIC DISTURBANCES AT THE PATIENTS WITH ISCHEMIC HEART AND BRAIN DESIASES BY MEANS OF COMBINATION OF PHARMACOLOGICAL DRUGS AND EXTRACORPOREAL AUTOBLOOD-MAGNET-THERAPY
|
| Kruchinsky N.G., Teplyakov A.I., Zubovsky D.K. |
| |
|
CORRECTION OF HAEMORRHAGIC DISORDERS AFFECTING PLATELETS: GENE THERAPY RESTORES HEMOSTASIS WITHIN A CANINE MODEL FOR GLANZMANN THROMBASTHENIA
|
| Wilcox D.A., Fang J., Jensen E.S., Du L.M., Boudreaux M.K. |
| |
|
CORRECTION OF TH1 DOMINANT CYTOKINE PROFILES BY HIGH DOSE DEXAMETHASONE IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA
|
| Guo C.S., Chu X.X., Shi Y., Li L.Z., Wang L., Wang Y.X., Peng J., Hou M. |
| |
|
CORRELATION BETWEEN A HIGHER LEVEL OF ACA WITH THE HEMOSTASIS ABNORMALITIES AMONG ADULT -THALASSEMIA
|
| Djumhana Atmakusuma T., Reksodiputro A., Tambunan K., Setyaningsih I. |
| |
|
CORRELATION BETWEEN DIFFERENT FIBRINOLYTIC TESTS IN PATIENTS WITH OBSTETRIC COMPLICATIONS
|
| Adamczuk Y.P., Iglesias Varela M.L., Martinuzzo M.E., Cerrato G.S., Forastiero R.R. |
| |
|
CORRELATION BETWEEN SCD40L LEVELS AND METALLOPROTEINASE EXPRESSION WITH THE PLATELET FUNCTIONAL RESPONSE IN IMMUNOLOGICAL DISEASES
|
| Butta N.V., Garcia-Rodriguez M., Arias-Salgado E., Fontela T., Larrucea S., Marin I., Menchen L., Hernandez-Sampelayo P., Parrilla R. |
| |
|
CORRELATION BETWEEN THE POTENCY OF A BETA2-GLYCOPROTEIN I DEPENDENT LUPUS ANTICOAGULANT AND THE LEVEL OF RESISTANCE TO ACTIVATED PROTEIN C
|
| de Laat B., Eckmann C., van Schagen M., Mertens K., van Mourik J. |
| |
|
CORRELATION OF HDL CHOLESTEROL WITH SOME LABORATORY PARAMETERS AND CAROTID ARTERIES ATHEROSCLEROTIC LESIONS IN PATIENTS WITH HEART ISCHEMIC DESEASES
|
| Akhvlediani M., Vorobiova E., Vakhtangadze T.K. |
| |
|
CORRELATION OF METABOLIC SYNDROME WITH ATHEROGENIC PHENOTYPES IN INDIAN POPULATION
|
| Kanjilal S., Shanker J., Rao V., Natesha B.K., Mukherjee M., Kakkar V.V. |
| |
|
CORRELATION OF PF4 ELISA (PF4) OPTICAL DENSITY RESULTS AND CLINICAL FINDINGS TO ACCURATELY DIAGNOSE HEPARIN INDUCED THROMBOCYTOPENIA (HIT)
|
| Tcherniantchouk O., Alsabeh R., Lee S. |
| |
|
CORRELATIONS BETWEEN ADAMTS13 ACTIVITY AND INHIBITOR LEVELS: OBSERVATIONS AND IMPLICATIONS FOR RESOURCE UTILIZATION
|
| Friedman K.D., Raife T.J., Endres J.L., Pietz B.C. |
| |
|
CORTICAL NEURONS AGGREGATE IN RESPONSE TO PLASMIN FORMED AT THEIR SURFACE BY TPA
|
| Ho-Tin-Noe B., Enslen H., Corsi J., Lijnen R., Angles-Cano E. |
| |
|
COST-EFFECTIVENESS (CE) OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) VS. RECOMBINANT FVIIA IN PROPHYLAXIS IN HEMOPHILIA PATIENTS WITH INHIBITORS
|
| Bonnet P., Yoon B., Ewenstein B., Wong W. |
| |
|
COST-EFFECTIVENESS OF COMPUTER-ASSISTED ANTICOAGULANT DOSAGE
|
| Jowett S., Bryan S., Keown M., Ibrahim S., Poller L., van den Besselaar A.M.H.P., van der Meer F.J.M., Palareti G., Roberts C., Shiach C., Tripodi A., Jespersen J., Lowe G.D.O. |
| |
|
COST-EFFECTIVENESS OF COMPUTER-ASSISTED ANTICOAGULANT DOSAGE CLINICAL STUDY
|
| Poller L., Keown M., Ibrahim S., van den Besselaar A.M.H.P., Bryan S., van der Meer F.J.M., Palareti G., Roberts C., Shiach C., Tripodi A., Jespersen J., Lowe G.D.O. |
| |
|
COULD HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS BE A RARE MANIFESTATION OF ANTIPHOSPHOLIPID ANTIBODY SYNDROME?
|
| Oláh Z., Schlammadinger A., Mikita J., Ilonczai P., Rázsó K., Bereczky Z., Boda Z. |
| |
|
COUNTS OF CD14++CD16+ MONOCYTES PREDICT CARDIOVASCULAR EVENTS IN DIALYSIS PATIENTS
|
| Heine G.H., Ulrich C., Kohler H., Girndt M. |
| |
|
COVALENT ANTITHROMBIN-HEPARIN COMPLEX NEUTRALIZES PROCOAGULANT ACTIVITY INDUCED BY VENTILATION IN NEWBORNS
|
| Chan A.K.C., Jayasuriya K., Parmar N., Berry L.R., Belik J. |
| |
|
COVALENT ANTITHROMBIN-HEPARIN COMPLEX REDUCES BRAIN EMBOLI DURING HYPOTHERMIC CARDIOPULMONARY BYPASS IN PIGS
|
| Chan A.K.C., Berry L.R., Tressel P., Weitz J.I., Hirsh J., Liao P., Klement P. |
| |
|
CPU INHIBITION WITH AZD9684: PROFIBRINOLYTIC EFFECTS IN ACUTE PE PATIENTS
|
| Eriksson H., Jensen E., Sandset P.M., Wall U., Andersson M., Nerme V., Eriksson-Lepkowska M., Wåhlander K. |
| |
|
C-REACTIVE PROTEIN, LIPOPROTEIN(A) AND HOMOCYSTEINE AS CONTRIBUTORS TO FIBRIN CLOT PERMEABILITY AND LYSABILITY IN SUBJECTS SCHEDULED FOR CORONARY ARTERY BYPASS GRAFTING
|
| Stepien E., Plicner D., Maciejewska-Sniezek M., Pazdan A., Zielinski L., Nosal M., Undas A., Drwila R., Kapelak B., Sadowski J. |
| |
|
CRITICAL ROLE FOR CYCLOPHILIN D (CYPD) AND THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (MPTP) IN THE REGULATION OF PLATELET ACTIVATION AND THROMBOSIS
|
| Jobe S.M., Wilson K.M., Leo L., Raimondi A., Molkentin J.D., Lentz S.R., Di Paola J. |
| |
|
CROSS REACTION OF ANTIBODY AGAINST HELICOBACTER PYLORI UREASE B WITH PLATELET GLYCOPROTEIN IIIA AND ITS SIGNIFICANCE IN THE PATHOGENESIS OF ITP
|
| Wang Z., Bai Y., Bai X., Ruan C. |
| |
|
CROSS-TALK OF VWF/GPIB- AND NO/CGMP-INDUCED SIGNALING IN HUMAN PLATELETS
|
| Walter U., Herterich S., Koessler J., Steigerwald U., Gambaryan S. |
| |
|
CRYO-EM OF MOLECULAR MACHINES AND CELLS
|
| Chiu W. |
| |
|
CRYOPRECIPITATE-REMOVED PLASMA AS A SOURCE OF FACTOR IX IN THE TREATMENT OF HEMOPHILIA B
|
| Lepatan L.P., Hernandez F.G., Montoya M.M., Ong J.B., Rodriguez E.V., Chua M.N. |
| |
|
CRYSTAL STRUCTURE OF THE C2 DOMAIN OF LACTADHERIN
|
| Shao C., Head J.F., Seaton B.A., Gilbert G.E. |
| |
|
CRYSTAL STRUCTURE OF THE HPC-4 FAB IN COMPLEX WITH PROTEIN C EPITOPE PEPTIDE
|
| Garteiser P., Mather T. |
| |
|
CURRENT PRACTICE IN THROMBOSIS AND HAEMOSTASIS: A SINGLE-CENTER RETROSPECTIVE STUDY
|
| Lambert C.M., Hermans C.R. |
| |
|
CUTANEOUS DELAYED-TYPE IV-HYPERSENSITIVITY REACTION (DTH) TO HEPARIN AND HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II (HIT) IS THERE AN ASSOCIATION ?
|
| Schindewolf M., Ludwig R.J., Kroll H., Boehncke W.H., Lindhoff-Last E. |
| |
|
CUTANEOUS REACTION TO LOW MOLECULAR WEIGHT HEPARIN AND HOMOZYGOUSIS FOR FACTOR V LEIDEN MUTATION DURING PREGNANCY: A CASE REPORT
|
| Mathonnet F.T., Uzan M., Fischer C., Nizard J., Jaouen E., Rozenberg P., Tabary N., Ville Y., Giudicelli Y. |
| |
|
CYCLOOXYGENASE-2 IS CRITICAL FOR HYDROGEN PEROXIDE-MEDIATED WOUND REPAIR IN HUMAN ENDOTHELIAL CELLS
|
| Eligini S., Arenaz I., Barbieri S.S., Faleri M.L., Tremoli E., Colli S. |
| |
|
CYP 2C19*2 AND MDR1+3435C ALLELES CONTRIBUTE TO LOW RESPONSE TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME
|
| Frere C., Cuisset T., Morange P., Quilici J., Saut N., Camoin L., Aillaud M., Bonnet J., Juhan-Vague I., Alessi M. |
| |
|
CYP2C19*2 POLYMORPHISM INFLUENCES PLATELET FUNCTIONNALITY IN RESPONSE TO CLOPIDROGEL TREATMENT
|
| Boval B., Peoc'h K., Bal dit Sollier C., Henry P., Houdard E., Crassard I., Bellucci S., Drouet L. |
| |
|
CYSTIC FIBROSIS HETEROZYGOTES DO NOT HAVE INCREASED PLATELET ACTIVATION
|
| Tarnow I., O'Sullivan B.P., Frelinger III A.L., Linden M.D., Li Y., Fox M.L., Barnard M.R., Michelson A.D. |
| |
|
CYTOKINE-INDUCED MONOCYTE-ENDOTHELIAL CELL INTERACTIONS: EFFECT ON PAI-1 LEVELS
|
| Valgañón M., Orbe J., Rodriguez J.A., Belzunce M., Paramo J.A. |
| |
|
CYTOMEGALOVIRUS AND HIGH RISK OF (RECURRENT) VENOUS THROMBOSIS AFTER RENAL TRANSPLANTATION
|
| Lijfering W.M., de Vries A.P.J., Veeger N.J.G.M., van Son W.J., Bakker S.J.L., van der Meer J. |
| |
|
CYTOPROTECTION AND ANTICOAGULATION BY ACTIVATED PROTEIN C ON CIRCULATING MICROPARTICLE-ASSOCIATED ENDOTHELIAL PROTEIN C RECEPTOR
|
| Perez-Casal M., Downey C., Toh C. |
| |
